» Current opinions on how to identify and treat NTRK fusion positive cancer

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

Current opinions on how to identify and treat NTRK fusion positive cancer

Prof. David Hong, Prof. Ezra Cohen, Prof. Frederique Penault-Llorca

We recently delivered a virtual Experts Knowledge Share meeting discussing how to identify, test and treat NTRK fusion positive cancer.

Prof. David Hong

Medical Oncologist

MD Anderson Cancer Center, Houston

United States (US)

Prof. Ezra Cohen

Medical Oncologist

Moores Cancer Center, San Diego

United States (US)

Prof. Frederique Penault-Llorca

Pathologist

University of Clermont-Ferrand

France

Prof. Ezra Cohen

Medical Oncologist

Moores Cancer Center, San Diego

United States (US)

Ezra Cohen, MD, is co‐Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. A physician‐scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted and immunotherapy. His research has received peer‐reviewed funding in the study of epidermal growth factor receptor inhibitors, cell therapy, and immunotherapy in head and neck cancer. He has made major contributions to the understanding of critical signaling pathways, integration of novel agents into standard of care, and definition of mechanisms to overcome resistance to drug therapy. He has also recently co‐developed a personalized neoantigen vaccine using unique cancer mutations to boost an anti‐tumor immune response. Dr. Cohen is Associate Director for Translational Science and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is chair of the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, and the Cancer Center’s Executive Committee. Dr. Cohen recently served as editor‐in‐chief of Oral Oncology, the highest impact specialty journal in head and neck cancer, and currently serves as senior editor for Clinical Cancer Research. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. Dr. Cohen has authored more than 170 papers and has presented his research at national and international meetings. In addition, he has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research. Dr. Cohen completed residencies in Family Medicine at the University of Toronto and in Internal Medicine at Albert Einstein College of Medicine. He completed a Hematology/Oncology fellowship at the University of Chicago where he was named chief fellow. Prior to his arrival in San Diego, Dr. Cohen was Co‐Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/ Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. A dedicated educator, Dr. Cohen also mentored and developed young faculty in his program.

Prof. Ezra Cohen has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Frederique Penault-Llorca

Pathologist

University of Clermont-Ferrand

France

Frédérique PENAULT-LLORCA, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Université d’Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Professor PENAULT-LLORCA is currently professor of Pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin, Clermont-Ferrand, France, and Vice-President of UNICANCER GROUP. She chairs the Immuno- Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies (ESMO, ASCO, ECP, AIP, SFP. Her main areas of interest as a pathology being female cancers. Professor PENAULT-LLORCA has conducted various biomarkers-based research studies in breast, ovarian, colorectal, gastric, and lung cancer in relation to response to targeted therapies and immunotherapies. She also acts as a coordinating pathologist for various oncology trials. Professor PENAULT-LLORCA has written more than 440 peer-reviewed publications and several books on female cancers and biomarker testing methods and issues.

Prof. Frederique Penault-Llorca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

time | open 5 min |accreditation: EACCME | Jan 2021

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

PDF FILE

PPTX FILE

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

This programme is supported by an Independent Educational Grant from Bayer

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and ECMEC® is available. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest

Prof Valentina Guarneri

Interactive patient case

28 min

(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced ...

Sep 2023

Prof. Viktor Grünwald

Interactive patient case

11 min

Optimising treatment for advanced RCC

Jun 2023

Prof. David Hong

5 min

TRK fusion-positive cancer highlights from ASCO 2022

Jun 2022

Beth Wittmer

Prof. Hans Prenen

Podcast

20 min

Podcast: management of skin toxicity with multikinase inhibitors

Jun 2022

Prof. Chiara Cremolini

2 min

Update from ASCO 2022 - Rectal cancer & mCRC

Jun 2022

Prof. Sammy Saab

15 min

Response to immunotherapy in HCC: Real-world experience and treat...

Jun 2022

Prof. Jonathan Trent

2 min

Update from ASCO 2022 - Sarcoma

Jun 2022

Prof. Jonathan Trent

0 min

[DEMO] SARCOMA CONNECT update from ASCO 2022

May 2022

Screenshot of the video by Prof. Rebecca Dent

Dr. Rebecca Dent

Prof. Chiara Cremolini

Asst. Prof. Hans Lee

Prof. Jonathan Trent

0 min

Update From ASCO 2022 - Selected LBAs

May 2022

Brenda Martone

Assoc. Prof. Alicia Morgans

Podcast

30 min

Shared decision-making in nmCRPC: Treatment considerations to mai...

Jun 2022

Assoc. Prof. Tanya Dorff

Dr. Neal Shore

Podcast

30 min

Timing of ARSI and taxanes for mCRPC

Jun 2022

Assessing the management of hepatocellular cancer in Asia

Survey

2 min

Assessing the management of hepatocellular cancer in Asia

Jun 2022

Other programmes developed by Prof. Ezra Cohen

Prof. Ezra Cohen

Medical Oncologist

Moores Cancer Center, San Diego

United States (US)

Prof. Ezra Cohen

5 min

NTRK CONNECT Update from ASCO 2020

May 2020

Prof. Ezra Cohen

5 min

Key Publication Snapshot 3 – Characterisation of adverse events...

Oct 2020

Other programmes developed by Prof. Frederique Penault-Llorca

Prof. Frederique Penault-Llorca

Pathologist

University of Clermont-Ferrand

France

Prof. Frederique Penault-Llorca

5 min

Using immunohistochemistry to detect TRK fusion-positive cancer

May 2022

Prof. Frederique Penault-Llorca

Prof. Andrea Sartore-Bianchi

Podcast

20 min

Podcast: TRK fusion-positive GI cancers

Oct 2021

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.